ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/RET-inhibitor
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/RET-inhibitor
13
trial(s) found.
NCT06624059
Curative
Phase 3
Recruiting
A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients With Resectable Stage I-III Non-Small Cell Lung Cancer, Selected According to Biomarker Status (
HORIZON-2
)
ALK/RET inhibitor
ALK inhibitor
ALK inhibitor,second generation
Alectinib
Carboplatin
Cisplatin
Pemetrexed
RET inhibitor
antimetabolite
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,RET-targeting
cytotoxic chemotherapy
platinum-based antineoplastic agent
+ ALK/RET inhibitor
Non-small cell lung cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05536141
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors (
ARC-20
)
HIF2a inhibitor
+ AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
Clear cell renal cell carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
SA
5037 - Glandore - Ashford Cancer Centre
NCT05170204
Curative
Phase 3
Recruiting
A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (
BO42777
)
ALK/RET inhibitor
ALK inhibitor
ALK inhibitor,second generation
ALK inhibitor,third generation
Alectinib
Durvalumab
Entrectinib
RET inhibitor
ROS1 inhibitor
TRK inhibitor
TRK inhibitor,first generation
anti-PD-L1 monoclonal antibody
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,RET-targeting
cancer therapy,ROS1-targeting
cancer therapy,TRK-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,PD-L1-targeting
+ ALK/RET inhibitor
Non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital (WITHDRAWN)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (WITHDRAWN)
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT04164199
Advanced
Phase 3
Enrolling by invitation
An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies (
BGB-A317-290-LTE1
)
PARP inhibitor
anti-PD-1 monoclonal antibody
+ KIT/PDGFR/RET/VEGFR inhibitor
Cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT03970447
Advanced
Phase 2 / Phase 3
Recruiting
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM (
GBM-AGILE
)
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,first generation
Lomustine
PDGFR inhibitor
PI3K-delta inhibitor
PI3K alpha inhibitor
PI3K inhibitor
Paxalisib
Pegargiminase
RET inhibitor
Radiotherapy
Regorafenib
Temozolomide
VAL-083
VEGFR inhibitor
alkylating agent
arginine deiminase-polyethylene glycol conjugate
cancer therapy
cancer therapy,FGFR-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PI3K-delta-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,RET-targeting
cancer therapy,VEGFR-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
dual PI3K/mTOR inhibitor
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
+ KIT/PDGFR/RET/VEGFR/FGFR inhibitor
Glioblastoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
ACTRN12624000532505
Advanced
Phase 3
Recruiting
International clinical research programme to improve outcomes in newly diagnosed Ewing sarcoma – Trial 1 (
INTER-EWING-1
)
Cyclophosphamide
Doxorubicin
Etoposide
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
Ifosfamide
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,first generation
PDGFR inhibitor
RET inhibitor
Radiotherapy
Regorafenib
VEGFR inhibitor
Vincristine
Vinorelbine
alkylating agent
anthracycline
cancer therapy
cancer therapy,FGFR-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFR-targeting
cancer therapy,RET-targeting
cancer therapy,VEGFR-targeting
cytotoxic chemotherapy
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
topoisomerase inhibitor
vinca alkaloid
+ KIT/PDGFR/RET/VEGFR/FGFR inhibitor
Ewing sarcoma
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05425940
Advanced
Phase 3
Active not recruiting
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (
STELLAR-303
)
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
MET/VEGFR2/AXL/MER inhibitor
anti-PD-L1 monoclonal antibody
Colorectal cancer
NSW
2200 - Bankstown - Bankstown-Lidcombe Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.9016 - Dunedin - Dunedin Hospital
NCT05328908
Advanced
Phase 3
Active not recruiting
A Phase 3, Randomized, Open-label Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants With Later-lines of Metastatic Colorectal Cancer (
RELATIVITY-123
)
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
Tipiracil Hydrochloride
Trifluridine
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
antimetabolite
thymidine phosphorylase inhibitor
Colorectal adenocarcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2650 - Wagga Wagga - Riverina Cancer Care Centre
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05198934
Advanced
Phase 3
Active not recruiting
A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator's Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation (
CodeBreak300
)
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KRAS G12C/NRAS G12C/HRAS G12C inhibitor
anti-EGFR monoclonal antibody
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT03906331
Advanced
Approved for marketing
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
RET-selective inhibitor
RET inhibitor
Selpercatinib
cancer therapy
cancer therapy,RET-targeting
+ RET-selective inhibitor
Breast cancer
Colon adenocarcinoma
Medullary thyroid cancer
Non-small cell lung cancer
Pancreatic cancer
Papillary thyroid cancer
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4032 - Chermside - The Prince Charles Hospital
WA
6009 - Nedlands - Linear Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT03685448
Advanced
Phase 2
Unknown
A Phase II of Single Agent Cabozantinib in Patients With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma Post Immunotherapy or Who Are Unsuitable for Immunotherapy (ANZUP1802) (
UNICAB
)
AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
AXL inhibitor
KIT inhibitor
MET inhibitor,type 2
RET inhibitor
ROS1 inhibitor
VEGFR2 inhibitor
Chromophobe renal cell carcinoma
Clear cell renal cell carcinoma
Sarcomatoid renal cell carcinoma
Type 1 papillary renal cell carcinoma
Type 2 papillary renal cell carcinoma
Xp11 translocation renal carcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3630 - Shepparton - Goulburn Valley Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5037 - Glandore - Ashford Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
NCT03170960
Advanced
Phase 1 / Phase 2
Unknown
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors (
XL184-021
)
AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
AXL inhibitor
KIT inhibitor
MET inhibitor,type 2
RET inhibitor
ROS1 inhibitor
VEGFR2 inhibitor
anti-PD-L1 monoclonal antibody
Differentiated thyroid carcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3021 - St Albans - Western Health - Sunshine Hospital
NCT02773524
Advanced
Phase 3
Unknown
A Randomised Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) (
INTEGRATEIIa
)
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
placebo
Gastroesophageal cancer
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2305 - New Lambton Heights - Newcastle Private Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2485 - Tweed Heads - The Tweed Hospital
2640 - Albury - Border Medical Oncology Research Unit
ACT
2605 - Garran - The Canberra Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5035 - Ashford - Flinders Medical Centre, Ashford Cancer Centre Research
5042 - Bedford Park - Flinders Medical Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (5)
Active not recruiting (3)
Unknown (3)
Enrolling by invitation (1)
Approved for marketing (1)
Recruitment Country and State
NSW (12)
VIC (11)
SA (7)
WA (6)
QLD (6)
NZ (5)
ACT (1)
NT (1)
TAS (1)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (1)
Phase 2 (1)
Phase 2 / Phase 3 (1)
Phase 3 (8)
Trial Type
Advanced (11)
Curative (2)
Cancer Therapy Class
RET
100%
KIT
77%
VEGFR
77%
PDGFR
54%
PD-1/PD-L1
46%
FGFR
46%
FGFR1
46%
FGFR1/2/3
46%
FGFR2
46%
FGFR3
46%
FGFR4
46%
VEGFR2
38%
AXL
31%
MET
31%
ROS1
31%
PD-1
23%
PD-L1
23%
ALK
15%
LAG3
15%
HIF2a
8%
TRK
8%
ERBB2
8%
HPK1
8%
OX40
8%
PARP
8%
TIGIT
8%
VEGF
8%
VEGFR1
8%
VEGFR3
8%
PI3K-delta
8%
PI3K
8%
PI3Kalpha
8%
mTOR
8%
mTORC1
8%
mTORC2
8%
MER
8%
EGFR
8%
HRAS G12C
8%
KRAS
8%
KRAS G12C
8%
NRAS G12C
8%
AR
8%
CYP17A1
8%
androgen axis
8%
Facility
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (5)
3000 - Melbourne - Peter MacCallum Cancer Centre (5)
2050 - Camperdown - Chris O'Brien Lifehouse (5)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (5)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (4)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (4)
3168 - Clayton - Monash Medical Centre (4)
5011 - Woodville South - The Queen Elizabeth Hospital (4)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (4)
5042 - Bedford Park - Flinders Medical Centre (4)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (3)
2109 - North Ryde - Macquarie University Hospital (3)
2031 - Randwick - Prince of Wales Hospital (3)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (3)
2640 - Albury - Border Medical Oncology Research Unit (3)
3128 - Box Hill - Box Hill Hospital - Eastern Health (2)
5037 - Glandore - Ashford Cancer Centre (2)
2065 - St Leonards - GenesisCare North Shore Private Hospital (2)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (2)
3021 - St Albans - Western Health - Sunshine Hospital (2)
2217 - Kogarah - St George Hospital (2)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (2)
6009 - Nedlands - One Clinical Research (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
2200 - Bankstown - Bankstown-Lidcombe Hospital (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
2650 - Wagga Wagga - Riverina Cancer Care Centre (1)
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
4032 - Chermside - The Prince Charles Hospital (1)
6009 - Nedlands - Linear Clinical Research (1)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (1)
2640 - Albury - Albury Wodonga Regional Cancer Centre (1)
3630 - Shepparton - Goulburn Valley Health (1)
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2305 - New Lambton Heights - Newcastle Private Hospital (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
2485 - Tweed Heads - The Tweed Hospital (1)
2605 - Garran - The Canberra Hospital (1)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
5035 - Ashford - Flinders Medical Centre, Ashford Cancer Centre Research (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
7000 - Hobart - Royal Hobart Hospital (1)
Cancer Type
Cancer
Solid tumour
Gastrointestinal cancer
Colorectal cancer
Lower gastrointestinal cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
Clear cell renal cell carcinoma
Kidney cancer
Urogenital cancer
Colorectal adenocarcinoma
Differentiated thyroid carcinoma
Endocrine gland cancer
Thyroid cancer
Upper gastrointestinal cancer
Central nervous system cancer
Glioblastoma
Glioma
High-grade glioma
Malignant glioma
Neurological cancer
Bone cancer
Ewing family of tumours
Ewing sarcoma
Primitive neuroectodermal tumour
Sarcoma
Breast cancer
Colon adenocarcinoma
Medullary thyroid cancer
Pancreatic cancer
Pancreatobiliary cancer
Papillary thyroid cancer
Chromophobe renal cell carcinoma
Non-clear cell renal cell carcinoma
Papillary renal cell carcinoma
Sarcomatoid renal cell carcinoma
Type 1 papillary renal cell carcinoma
Type 2 papillary renal cell carcinoma
Xp11 translocation renal carcinoma
Gastroesophageal cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy